Phibro Animal Health just finished its first complete year since folding in a large medicated feed additive business, and the headline numbers look impressive. Full-year net sales topped $1.5 billion. Adjusted earnings per share jumped 48% to $3.22. Operating profit (before interest, tax, depreciation and amortization) climbed 39% to $255 million. On an earnings call August 27, management argued the deal is finally paying off.

The messier story is one level down.

What actually happened

Phibro's acquired feed additive portfolio grew 70% in its first full year inside the company, adding $354 million in sales. But the broader picture held up too, which matters. The company's Animal Health segment rose 21% overall. Mineral Nutrition, which covers zinc, copper and trace minerals, climbed 11% on stronger demand. Vaccine sales rose 14%, driven largely by poultry demand in Latin America and Israel. A companion animal joint health product called Rejensa posted what management described as a "nice uptick" as distribution expanded. That kind of spread across product lines suggests Phibro isn't simply renting its growth from one acquisition.

Chief Operating Officer Larry Miller pointed to livestock values sitting at all-time highs as a tailwind: when a farmer's animals are worth more, that farmer spends more to keep them healthy. It's a simple mechanism, but a real one.

Where the numbers get uncomfortable

For all the profit growth, Phibro generated just $9.9 million in free cash flow last year. The gap between strong operating profit and nearly zero free cash comes mostly from an $86.3 million buildup in inventory tied to the acquired portfolio. Cash tied up in unsold goods is not cash available to pay down debt or fund the next move.

The balance sheet is carrying $737.9 million in total debt. At 2.9 times annual operating profit, that leverage is manageable if growth holds, but it leaves limited cushion if conditions shift. Livestock values are high now, but animal health spending tends to follow farm profitability, and farm profitability follows commodity prices, which move.

Guidance for fiscal 2027 calls for net sales of $1.55 billion to $1.6 billion and operating profit of $258 million to $268 million. At the midpoint, that's roughly 4% sales growth and 3% operating profit growth, a sharp deceleration from this year's pace. Part of that is simply math: when you've just posted a 70% growth year in an acquired division, the next year's comparison is brutal. The acquired portfolio itself fell 11% in the fourth quarter against a strong prior-year period.

Management also flagged that higher selling and administrative costs built up over the year will weigh on the first quarter of fiscal 2027, enough to push operating profit growth negative for that period.

The longer arc

Phibro is betting on a few structural tailwinds to carry it through the slowdown. Its three-year internal efficiency program concluded in June and is still expected to contribute roughly $50 million in cumulative operating profit benefit in fiscal 2027. A planned closure of its Chicago Heights plant is projected to save $15 million to $20 million a year once it takes full effect in fiscal 2028.

Those are real numbers. But they are cost savings, not revenue growth. A company that generates under $10 million in free cash while carrying nearly $740 million in debt needs the top line to keep growing, not just the cost line to keep shrinking.

The acquisition looks like a sound long-term bet on the structural demand for animal health products, an industry that grows steadily as global protein consumption rises and livestock farming intensifies. But the first full year has revealed the transition costs that balance sheet bets always carry. The next year will show whether Phibro can grow its way to financial flexibility, or whether the debt load starts to do the talking instead.